|
|
Volumn 5, Issue 6, 2010, Pages 857-861
|
|
Interview
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CARBIDOPA PLUS LEVODOPA;
DOPAMINE;
LEVODOPA;
BASAL GANGLION;
BRAIN CELL;
BRAIN DEPTH STIMULATION;
BRAIN FUNCTION;
CELL LOSS;
CELL POPULATION;
CELL THERAPY;
CELL TYPE;
CLINICAL TRIAL;
COMPARATIVE EFFECTIVENESS;
DISEASE ACTIVITY;
DISEASE CONTROL;
DISEASE COURSE;
DOPAMINERGIC NERVE CELL;
DRUG EFFICACY;
DRUG TREATMENT FAILURE;
DRUG WITHDRAWAL;
DYSKINESIA;
GABAERGIC SYSTEM;
HUMAN;
HUNTINGTON CHOREA;
NIGRONEOSTRIATAL SYSTEM;
NONHUMAN;
NOTE;
PARKINSON DISEASE;
PRIORITY JOURNAL;
STUDY DESIGN;
SYMPTOMATOLOGY;
THERAPY EFFECT;
TREATMENT DURATION;
TREATMENT PLANNING;
TREND STUDY;
ANIMAL;
ARTICLE;
CELL TRANSPLANTATION;
HISTORY;
INTERVIEW;
SWINE;
UNITED KINGDOM;
ANIMALS;
CELL TRANSPLANTATION;
DOPAMINE;
GREAT BRITAIN;
HISTORY, 20TH CENTURY;
HISTORY, 21ST CENTURY;
HUMANS;
PARKINSON DISEASE;
SUS SCROFA;
|
|
EID: 78649383179
PISSN: 17460751
EISSN: None
Source Type: Journal
DOI: 10.2217/rme.10.82 Document Type: Note |
|
Times cited : (2)
|
|
References (2)
|
